Around the world, Pulitzer Center grantees are reporting on misinformation related to science, climate change, elections, health issues, and fossil fuels. We believe the best way to counter this ...

Elevate your golf game with this Lilly Pulitzer matching set, featuring a UPF 50 jacket and skort in a fun pink gingham print for effortless style on the course. Add a touch of coastal charm to ...

Eli Lilly reported third-quarter results before the market opened on Wednesday. Management missed Wall Street estimates and lowered earnings guidance for 2024. Sales of Zepbound and Mounjaro ...

(AP Photo/Peter Morgan) Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] NEW YORK (AP) — U.S. stock indexes edged lower Wednesday after drops for Eli Lilly and chip companies ...

Eli Lilly and Company reported third quarter results and missed expectations and had to lower its guidance, which was a huge disappointment for investors. But in the last few years, Eli Lilly was ...

Lilly's shares fall 8% as drug sales miss expectations CEO David Ricks cited physical and financial constraints at wholesalers for the shortfall Lilly slashes annual profit forecast due to ...

Eli Lilly on Wednesday fell short of profit and revenue expectations for the third quarter, weighed down by disappointing sales of its blockbuster weight loss drug Zepbound and diabetes treatment ...

Copyright 2024 The Associated Press. All Rights Reserved. FILE - This April 26, 2017 file photo shows the Eli Lilly & Co. corporate headquarters in Indianapolis. (AP ...

AJ Mast / Bloomberg via Getty Images Eli Lilly (LLY) shares tumbled 12% at the opening bell Wednesday after its third-quarter results fell well short of analysts' estimates and it lowered its full ...

Drug maker Eli Lilly’s share price plunged Wednesday morning after the company reported worse third-quarter results than expected, especially in its weight-loss drug division, registering a rare ...

Eli Lilly (NYSE:LLY) shares fell ~9% in the premarket on Wednesday, sending ADRs of its rival Novo Nordisk (NVO) lower after the U.S. drugmaker missed Street forecasts with its Q3 2024 financials ...